No Data
No Data
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $175
J.P. Morgan analyst Anupam Rama maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $175.According to TipRanks data, the analyst has a success rate of 46.1%
S&P 500 Futures Drop In Premarket Trading; CAE Inc, Modine Manufacturing Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Analog Devices Inc. (ADI) was up 6.2% in pre-market
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Sarepta Therapeutics (SRPT)
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
12 Analysts Have This To Say About Sarepta Therapeutics
Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise overview
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Sol-Gel Technologies (SLGL)
No Data